<DOC>
	<DOC>NCT00272753</DOC>
	<brief_summary>The aim is to study whether the budesonide component within the budesonide/ formoterol combination inhaler has additive value in a model of "slow onset acute asthma" , namely three AMP provocation tests performed on one day</brief_summary>
	<brief_title>Effect of Budesonide / Formoterol Combination in Repeated AMP Provocations</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>asthma diagnosis according to ATS criteria, lung function (FEV1) above 60% of predicted, AMPPC20 below 160 mg/ml with a documented fall in FEV1 of 30% in this provocation test having smoked &gt; 10 Packyears, hypersensitivity to one of the study drugs, significant comorbidity, pregnancy or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>